Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Myrexis

Drug Profile

Research programme: cancer therapeutics - Myrexis

Alternative Names: MPC-0767; MPI-0479605; MPI-479605; MPI-487109; MPI-487901; MPYS 197; MPYS 413

Latest Information Update: 27 Feb 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Feb 2014 Discontinued - Preclinical for Cancer in USA (PO)
  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPC 0767 is available for out-licensing; Myrexis does not intend to further develop the compound itself (\www.myrexis.com\)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top